These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30635724)

  • 21. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
    Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
    Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    Sechi E; Zarbo R; Biancu MA; Chessa P; Idda ML; Orrù V; Lai S; Leoni S; Solla P
    J Neuroimmunol; 2021 Sep; 358():577666. PubMed ID: 34298341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
    Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M
    Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases.
    Memon AB; Javed A; Caon C; Srivastawa S; Bao F; Bernitsas E; Chorostecki J; Tselis A; Seraji-Bozorgzad N; Khan O
    PLoS One; 2018; 13(1):e0190425. PubMed ID: 29309416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders.
    Damato V; Theorell J; Al-Diwani A; Kienzler AK; Makuch M; Sun B; Handel A; Akdeniz D; Berretta A; Ramanathan S; Fower A; Whittam D; Gibbons E; McGlashan N; Green E; Huda S; Woodhall M; Palace J; Sheerin F; Waters P; Leite MI; Jacob A; Irani SR
    Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2121804119. PubMed ID: 35666871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.
    Palace J; Wingerchuk DM; Fujihara K; Berthele A; Oreja-Guevara C; Kim HJ; Nakashima I; Levy M; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Yountz M; Miller L; Armstrong R; Pittock S;
    Mult Scler Relat Disord; 2021 Jan; 47():102641. PubMed ID: 33310418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.
    Ongphichetmetha T; Jitprapaikulsan J; Siritho S; Rattanathamsakul N; Detweeratham T; Prayoonwiwat N
    Sci Rep; 2024 Feb; 14(1):3503. PubMed ID: 38347079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
    Cohen M; Romero G; Bas J; Ticchioni M; Rosenthal M; Lacroix R; Brunet C; Rico A; Pelletier J; Audoin B; Lebrun C
    J Neurol Sci; 2017 Feb; 373():335-338. PubMed ID: 28131216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
    Ahn SH; Kim SM; Sung JJ
    Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder.
    Gomez-Figueroa E; Noriega-Morales G; Casallas-Vanegas A; Zabala-Angeles I; Garcia-Estrada C; Neri D; Sarachaga AJ; Rivas-Alonso V; Corona-Vazquez T; Flores-Rivera J
    Clin Neurol Neurosurg; 2020 Sep; 196():106007. PubMed ID: 32559706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab.
    Nicolas P; Ruiz A; Cobo-Calvo A; Fiard G; Giraudon P; Vukusic S; Marignier R
    Front Immunol; 2019; 10():2686. PubMed ID: 31803192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey.
    Uzunköprü C; Tütüncü M; Gündüz T; Gümüş H; Şen S; Demir S; Çınar BP; Türe HS; Uygunoğlu U; Toğrol RE; Terzi M; Kürtüncü M; Özakbaş S; Tütüncü M; Beckmann Y; Siva A
    Int J Clin Pract; 2021 Jul; 75(7):e14158. PubMed ID: 33743552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study.
    Zhao D; Ren K; Lu J; Liu Z; Li Z; Wu J; Xu Z; Wu S; Lei T; Ma C; Zhao S; Bai M; Li H; Guo J
    Front Immunol; 2023; 14():1148632. PubMed ID: 37614240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.
    Flanagan EP; Levy M; Katz E; Cimbora D; Drappa J; Mealy MA; She D; Cree BAC
    Mult Scler Relat Disord; 2022 Jan; 57():103352. PubMed ID: 35158461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study.
    Paolilo RB; Hacohen Y; Yazbeck E; Armangue T; Bruijstens A; Lechner C; Apostolos-Pereira SL; Martynenko Y; Breu M; de Medeiros Rimkus C; Wassmer E; Baumann M; Papetti L; Capobianco M; Kornek B; Rostásy K; da Paz JA; Ciccarelli O; Lim M; Saiz A; Neuteboom R; Marignier R; Hemingway C; Sato DK; Deiva K
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32732259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
    Espiritu AI; Pasco PMD
    Mult Scler Relat Disord; 2019 Aug; 33():22-32. PubMed ID: 31136907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
    Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
    Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder.
    Cui L; Jiao J; Zhang Y; Wang R; Peng D; Jiao Y; Zhang W
    Mult Scler Relat Disord; 2024 Jun; 86():105600. PubMed ID: 38579568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
    JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.